EP2902039
Mótverkandi IL-17 mótefni
Status:
EP Einkaleyfi útrunniðEP appl. date:
4.8.2005EP published:
11.4.2018EP application number:
15156029.9
EP translation filed:
23.5.2018Grant published:
15.6.2018EPO information:
European Patent Register
Max expiry date:
3.8.2025Expiry date:
3.8.2025
Title:
IL-17 antagonistic antibodies
Timeline
Today
4.8.2005EP application
11.4.2018EP Publication
23.5.2018Translation submitted
15.6.2018Registration published
3.8.2025Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056, Basel, CH
Inventor
Name:
Di Padova, Franco EAddress:
Birsfelden, CH
Name:
Gram, HermannAddress:
Weil am Rhein, DE
Name:
Hofstetter, HansAddress:
Riehen, CH
Name:
Jeschke, MargitAddress:
Basel, CH
Name:
Rondeau, Jean-MichelAddress:
Basel, CH
Name:
Van Den Berg, WimAddress:
CB Molenhoek, NL
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
0417487Date:
5.8.2004Country:
GB
Supplementary protection
SPC number:
SPC239
Classification
Categories:
A61K 39/395, A61P 29/00, C07K 16/24
Annual fees
Number
Paid
Expires
Payer
Number: 14
Paid: 31.5.2018
Expires: 3.8.2019
Payer: Árnason Faktor
Number: 15
Paid: 23.7.2019
Expires: 3.8.2020
Payer: Árnason Faktor
Number: 16
Paid: 24.7.2020
Expires: 3.8.2021
Payer: Árnason Faktor ehf.
Number: 17
Paid: 23.7.2021
Expires: 3.8.2022
Payer: Árnason Faktor ehf.
Number: 18
Paid: 27.7.2022
Expires: 3.8.2023
Payer: Árnason Faktor ehf.
Number: 19
Paid: 26.7.2023
Expires: 3.8.2024
Payer: Árnason Faktor ehf.
Number: 20
Paid: 23.7.2024
Expires: 3.8.2025
Payer: Árnason Faktor ehf.